The new 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026 ACC/AHA Dyslipidemia Guideline) includes important updates for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). This document replaces the recommendations published in the 2018 cholesterol guideline and reinforces the importance of earlier cardiovascular risk assessment, individualized therapeutic goals, and optimized cholesterol management and lipid management strategies.
Below is an overview of the most important updates and recommendations that may influence everyday clinical practice and cardiovascular disease prevention strategies.
Early Dyslipidemia and Cholesterol Management to Reduce Cardiovascular Risk
The 2026 ACC/AHA Guideline recommends earlier treatment of dyslipidemia. It emphasizes the importance of adopting healthy lifestyle habits from a young age, ideally with appropriate professional counseling focused on heart disease prevention and cardiovascular health. In addition, the guideline also recommends considering pharmacologic therapy in young patients with familial hypercholesterolemia. Also considers early pharmacologic intervention in:
- Young individuals with familial hypercholesterolemia
- Young adults with high LDL cholesterol (LDL-C ≥160 mg/dL)
- Patients with a strong family history of premature ASCVD
PREVENT and CPR Model: A New Approach to Cardiovascular Risk Assessment
- Use the American Heart Association’s updated Predicting Risk of Cardiovascular Disease Events (PREVENT) equations to assess 10-year and 30-year cardiovascular risk.
- The goal is earlier prevention in adults aged 30 to 79 years.
- Use the CPR model (Calculate–Personalize–Reclassify) to:
A) Calculate the 10-year ASCVD (atherosclerotic cardiovascular disease) risk
B) Personalize the estimated risk for each patient by considering factors not included in the PREVENT-ASCVD equations
C) Reclassify risk, when appropriate, through the selective use of coronary artery calcium (CAC) scoring and reassess therapeutic management
This updated strategy supports more personalized preventive cardiology and cholesterol treatment decisions.
When to Initiate LDL-Cholesterol Lowering Therapy
Clinicians may consider LDL cholesterol-lowering therapy for primary prevention in adults with an estimated 10-year ASCVD risk of 3% to <5% (borderline risk) based on PREVENT-ASCVD. The guideline also recommends shared decision-making when considering therapy initiation for patients with a 10-year risk of 5% to <10% (intermediate risk).
New LDL-C and Non–HDL-C Targets in the 2026 ACC/AHA Multisociety Dyslipidemia Guideline
LDL cholesterol goals and non–HDL-C treatment targets once again play an important role important role to guide lipid-lowering therapy. In addition, percentage LDL-C reduction remains a major therapeutic priority across all patient populations.
The target percentage reduction should be individualized according to each patient’s ASCVD risk profile and overall cardiovascular risk factors.
ApoB and Residual Cardiovascular Risk: What the 2026 Guideline Recommends
Measurement of apolipoprotein B (ApoB) may help improve cardiovascular risk assessment and guide therapy after LDL-C and non–HDL-C goals have been achieved, particularly in patients with:
- Elevated triglycerides (>200 mg/dL)
- Diabetes
- Low LDL-C levels (<70 mg/dL)
ApoB testing may help identify residual cardiovascular risk related to lipoproteins that can be underestimated by the standard lipid panel alone. It may also support the diagnosis of specific lipid and lipoprotein disorders.
Lp(a) or Lipoprotein(a): A Cardiovascular Risk-Enhancing Factor
The guideline recommends measuring lipoprotein(a) [Lp(a)] at least once during a patient’s lifetime to identify individuals at increased ASCVD risk and inherited cardiovascular disease risk.
Elevated Lp(a) Levels and Their Clinical Impact
- Lp(a) levels ≥125 nmol/L (50 mg/dL) are considered a cardiovascular risk-enhancing factor and are associated with an approximately 1.4-fold increase in ASCVD risk.
- Levels ≥250 nmol/L (100 mg/dL) are associated with an estimated ≥2-fold increase in cardiovascular risk.
Elevated Lp(a) should prompt more intensive LDL cholesterol reduction and optimization of additional cardiovascular risk factors.
Coronary Artery Calcium (CAC): A Key Tool for Risk Reclassification
Coronary artery calcium (CAC) scoring may improve cardiovascular risk stratification and help guide LDL-C and non–HDL-C targets in:
- Men ≥40 años
- Women ≥45 años
Why CAC Has Prognostic Value
Both absolute CAC burden and the corresponding age-, sex-, and race-adjusted percentile provide prognostic information and may help reclassify cardiovascular risk in adults undergoing heart disease risk assessment.
Cholesterol Management in Patients With Diabetes, CKD, or HIV
LDL-lowering therapy is recommended for primary prevention in adults aged 40 to 75 years with:
- Diabetes
- Chronic kidney disease (CKD) stages 3 or 4
- HIV infection
These recommendations apply regardless of baseline LDL-C levels. After age 75 years, LDL-C–lowering pharmacotherapy may still be considered in combination with lifestyle interventions to reduce ASCVD risk.
More Aggressive LDL-C Targets in Secondary Prevention
For secondary prevention, the 2026 ACC/AHA Multisociety Guideline recommends the following goals in patients at very high ASCVD risk:
- LDL-C <55 mg/dL (1.4 mmol/L)
- no–HDL-C <85 mg/dL (2.2 mmol/L)
Although a smaller subset of ASCVD patients not considered very high risk may have an LDL-C goal of <70 mg/dL, most patients with prior ASCVD events will likely qualify for more intensive cholesterol lowering treatment and stricter LDL-C targets (<55 mg/dL).
Elevated Triglycerides: Statins Remain the Foundation of Therapy
In patients with persistently elevated triglycerides (TG), statins remain the cornerstone of pharmacologic therapy. Combined with lifestyle modification, they help reduce ASCVD risk and improve cardiovascular outcomes.
Preventing Pancreatitis in Severe Hypertriglyceridemia
Additional triglyceride-lowering therapies may also be required to prevent pancreatitis, particularly in patients with severe hypertriglyceridemia and TG levels ≥1000 mg/dL (11.3 mmol/L).
Key Takeaways From the 2026 ACC/AHA Dyslipidemia Guideline
The 2026 ACC/AHA Guideline introduces a more preventive, individualized, and earlier approach to dyslipidemia management and LDL cholesterol management. The following image summarizes the key updates.
These recommendations aim to improve early cardiovascular risk identification and, ultimately, optimize therapeutic decision-making to reduce these types of events over the long term.
Cardiovascular Evaluation and Risk Stratification in Clinical Practice
The new ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA 2026 recommendations emphasize the importance of early cardiovascular risk screening and accurate cardiovascular evaluation. Therefore, supporting this assessment requires reliable diagnostic tools for advanced EKG testing, exercise stress testing, Holter monitoring, combined with advanced algorithms capable of delivering more comprehensive and accurate cardiovascular analysis.
For more than 50 years, SCHILLER has developed cardiopulmonary solutions designed to support clinical decision-making and optimize cardiovascular assessment. Request a demonstration to learn how these technologies can strengthen cardiovascular diagnostics, patient monitoring, and preventive cardiology workflows.
Frequently Asked Questions About the 2026 ACC/AHA Dyslipidemia Guideline
What is the 2026 ACC/AHA Dyslipidemia Guideline?
The 2026 ACC/AHA Dyslipidemia Guideline updates recommendations for cardiovascular risk assessment and LDL cholesterol management. It introduces new approaches for primary prevention, cardiovascular risk stratification, and the use of biomarkers such as ApoB and lipoprotein(a) [Lp(a)].
What are the main updates in the 2026 ACC/AHA Dyslipidemia Guideline?
Key updates include:
- Greater emphasis on early cardiovascular prevention
- Integration of PREVENT-ASCVD and coronary artery calcium (CAC) scoring
- Reintroduction of LDL-C and non–HDL-C therapeutic targets
- Selective use of ApoB
- Recommendation to measure Lp(a) at least once in all adults
Why is lipoprotein(a) [Lp(a)] important?
Lp(a) is a cardiovascular risk-enhancing factor associated with atherosclerotic cardiovascular disease (ASCVD). The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in a lifetime to help identify patients at increased cardiovascular risk.
What is the role of coronary artery calcium (CAC) scoring in the 2026 ACC/AHA Guideline?
Coronary artery calcium (CAC) scoring helps refine cardiovascular risk stratification in primary prevention. It may support decisions regarding initiation or intensification of lipid-lowering therapy.
What changes does the 2026 ACC/AHA Guideline propose for LDL cholesterol management?
The 2026 ACC/AHA guideline reemphasizes LDL cholesterol (LDL-C) and non–HDL-C therapeutic targets, particularly in patients with high cardiovascular risk or established ASCVD. The goal is to achieve more individualized and intensive lipid control.
: What is PREVENT-ASCVD?
PREVENT-ASCVD is the set of equations recommended by the 2026 ACC/AHA guideline to estimate 10-year ASCVD risk in primary prevention. It is intended for adults aged 30 to 79 years without ASCVD or subclinical atherosclerosis and with LDL-C levels of 70–189 mg/dL. The assessment also incorporates risk-enhancing factors and, when treatment uncertainty remains, CAC scoring for more individualized risk evaluation.
What does the 2026 ACC/AHA Dyslipidemia Guideline recommend?
The guideline recommends a more individualized and earlier approach to atherosclerotic cardiovascular disease (ASCVD) prevention. It also emphasizes comprehensive cardiovascular risk assessment and the use of tools such as PREVENT-ASCVD and coronary artery calcium (CAC) scoring.